BioWorld

May 8, 2002

Cephalon Partners Cancer Program With Novuspharma

In a three-year collaboration entered Tuesday with Cephalon Inc., Novuspharma SpA will use its preclinical research technology to screen a number of cancer compounds provided by Cephalon. (BioWorld Today) Read More

Arriva Arrives, Closes $28M Series D Round For Trials

Irradiating Mice Makes Their Cells Cancerous; Non-Irradiated Pups, Grand-Pups, Get Same Syndrome

Vasogen Raises $10.8M For Immune Modulation Therapy

Other News To Note

NeoTherapeutics Looking To License Out Drug Candidates

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...